KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Other Operating Expenses (2018 - 2025)

Historic Other Operating Expenses for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Q3 2025 value amounting to -$929000.0.

  • Aurinia Pharmaceuticals' Other Operating Expenses rose 7968.95% to -$929000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.1 million, marking a year-over-year decrease of 936.86%. This contributed to the annual value of $4.3 million for FY2024, which is 15187.97% up from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported Other Operating Expenses of -$929000.0 as of Q3 2025, which was up 7968.95% from -$9.2 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' Other Operating Expenses' 5-year high stood at $4.5 million during Q4 2024, with a 5-year trough of -$9.2 million in Q2 2025.
  • Its 5-year average for Other Operating Expenses is -$930894.7, with a median of -$55000.0 in 2021.
  • Per our database at Business Quant, Aurinia Pharmaceuticals' Other Operating Expenses skyrocketed by 154328.36% in 2021 and then crashed by 328827.59% in 2025.
  • Aurinia Pharmaceuticals' Other Operating Expenses (Quarter) stood at $285000.0 in 2021, then soared by 661.4% to $2.2 million in 2022, then tumbled by 518.16% to -$9.1 million in 2023, then surged by 149.66% to $4.5 million in 2024, then tumbled by 120.62% to -$929000.0 in 2025.
  • Its Other Operating Expenses was -$929000.0 in Q3 2025, compared to -$9.2 million in Q2 2025 and -$4.4 million in Q1 2025.